ConductScience.org, home

Comparison · NCT02014519-16f6deaf

Male Group vs Female Group: Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by Gender)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Male Group vs Female Group: Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by Gender). Trial comparisons, record NCT02014519-16f6deaf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02014519-16f6deaf

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.9850.9740.991wilson
Risk in group 20.9920.9850.996wilson
Risk difference, group 1 minus group 2-0.007-0.01880.00246newcombe hybrid score
Risk ratio, group 1 over group 20.9930.9831log
Odds ratio, group 1 over group 20.5370.2311.25log
Number needed to treat, for one fewer participant with the outcome on Male Group than on Female Group143from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Male GroupMale subjects aged 18 years and above who had agreed to collection of blood sample.775787OG000
Group 2Female GroupFemale subjects aged 18 years and above who had agreed to collection of blood sample.1,2021,212OG001

Outcome

Type
SECONDARY
Title
Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by Gender)
Description
The cut-off value for anti-PT IgG levels not indicative of current/recent infection was smaller than (\<) 1.0 OD units.
Time frame
At the time of enrollment of each subject (Day 0)
Population
The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available.

Source ClinicalTrials.gov

Trial

Title
A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary
NCT number
NCT02014519
Phases
NA
Conditions
Pertussis, Pertussis Vaccines
Interventions
Blood sampling, Data collection
Lead sponsor
GlaxoSmithKline
Results first posted
2018-12-17

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02014519-16f6deaf